Relevance of CYP3A5 Expression on the Clinical Outcome of Patients With Renal Cell Carcinoma

Anticancer Res. 2021 May;41(5):2511-2521. doi: 10.21873/anticanres.15029.

Abstract

Background/aim: This study aimed to elucidate the detailed characteristics of CYP3A5 expression and the association between CYP3A5 expression and clinical outcomes in patients with renal cell carcinoma (RCC).

Patients and methods: This study retrospectively enrolled 124 Japanese patients with RCC treated at the Okayama University Hospital. The commonest CYP3A5 gene polymorphism, CYP3A5*3, and expression levels of CYP3A5 mRNA and protein in each tissue were examined.

Results: Expression of CYP3A5 mRNA and protein in RCC tissues was significantly down-regulated compared to that in adjacent normal tissues. High level of CYP3A5 mRNA expression significantly extended cancer-specific survival (p=0.004) and overall survival (p=0.002). The CYP3A5 mRNA expression level was identified as a significant independent prognostic factor for both cancer-specific survival and overall survival.

Conclusion: CYP3A5 could serve as a potential marker for prognostication and treatment planning for patients with RCC.

Keywords: CYP3A5 protein; cytochrome P450 CYP3A; human; renal cell carcinoma treatment outcome.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Renal Cell / genetics
  • Carcinoma, Renal Cell / pathology
  • Carcinoma, Renal Cell / therapy*
  • Cytochrome P-450 CYP3A / genetics*
  • Disease-Free Survival
  • Female
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Male
  • Middle Aged
  • Prognosis*
  • Treatment Outcome

Substances

  • CYP3A5 protein, human
  • Cytochrome P-450 CYP3A